Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Acquires 6,250 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 6,250 shares of the business’s stock in a transaction on Friday, June 26th. The stock was acquired at an average price of $24.95 per share, with a total value of $155,937.50. Following the transaction, the chief financial officer owned 33,054 shares in the company, valued at approximately $824,697.30. The trade was a 23.32% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ:FTH opened at $22.87 on Friday. Sensei Biotherapeutics, Inc. has a twelve month low of $6.32 and a twelve month high of $36.76. The firm has a market capitalization of $30.69 million, a PE ratio of -0.16 and a beta of -0.25.

Analyst Upgrades and Downgrades

FTH has been the topic of a number of research reports. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $60.00 target price on the stock. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research report on Friday. They issued an “outperform” rating and a $57.00 price objective on the stock. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Finally, Weiss Ratings initiated coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.